Project Grant HT94252410824
Award Date
8/15/24
Completion Date
8/14/26
Dollars Obligated
$464K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
The Defense Health Agency awarded a $416,115 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Research Institute Of The Mcgill University Health Centre. The grant, awarded on August 15, 2024, will fund the development of next-generation prognostic tools for localized clear cell renal cell carcinoma through the integration of genomic, clinical, and pathological features. The award has a performance period ending on August 14, 2026. The Research...
This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
This federal Project Grant award, valued at $1,339,689.00 and provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to identify and characterize metastasis-driving tumor cell subpopulations in localized stage III clear cell renal cell carcinoma. The grant recipient, The Feinstein Institutes for Medical Research, will conduct this advanced biomedical and translational research over a 4-year period from August 1, 2024...
The Department of the Army Medical Command awarded a $116,692 Project Grant to the Royal Institution For The Advancement Of Learning / McGill under the Military Medical Research and Development program. The grant will fund a research project titled "UNDERSTANDING PHYSICAL DETERMINANTS OF HETEROGENEITY IN RENAL CANCER CARCINOMA" from July 15, 2021 to July 14, 2023. The project will be performed at 2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada. Through this funding, the awardee will...
The U.S. Department of Defense's Defense Health Agency awarded a $395,202 Project Grant to The University of Texas Southwestern Medical Center in Dallas, Texas under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "PET IMAGING OF HIF 2A IN RENAL CANCER," supports research to develop new imaging techniques for detecting and monitoring kidney cancer in military personnel and veterans. The three-year award, running from September 1, 2023 to August...
This $1,044,720 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to develop targeting kits using mono- and bi-paratopic antibody drug conjugates for chromophobe renal cell carcinoma. The award has an initial performance period from August 1, 2024 to July 31, 2027. The objective is to advance innovative therapeutic...
The Defense Health Agency awarded a $1,023,225 Project Grant under the Military Medical Research and Development program (CFDA# 12.420) to The Cleveland Clinic Foundation. The grant funds research to investigate the therapeutic relevance of targeting the anti-apoptotic Bcl-xL protein in kidney cancer. A sub-award to Harvard T.H. Chan School of Public Health will perform BH3 profiling to compare apoptotic responses in renal cell carcinomas under varied conditions, including treatment with BH3...
The Department of the Army Medical Command awarded a $390,033 Project Grant to Mount Sinai Hospital in Ottawa, Ontario, Canada to identify novel immune evasion tumor immune networks as targets for clear cell renal cell carcinoma immunotherapy. The grant was awarded on August 15, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research activities through August 14, 2025. The Military Medical Research and Development program aims to transform...
The Department of the Army Medical Command awarded a $475,457 Project Grant to the Institute of Cancer Research: Royal Cancer Hospital in the United Kingdom. The grant is part of the Military Medical Research and Development program (CFDA 12.420) and will fund research characterizing biomarkers of growth and progression in small renal masses from September 30, 2022 to September 29, 2025. Through this award, the grantee will investigate medical solutions for the battlefield by transforming...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $999,096.00 to The University of Texas Southwestern Medical Center to conduct research on "Targeting DNA Damage Response to Treat Clear Cell Renal Cell Carcinoma." The award period runs from July 1, 2024 to June 30, 2028. The research aims to develop new treatments for clear cell renal cell carcinoma, a type of kidney cancer, by investigating...